Pharmacogenomics of Sex Difference in Chemotherapeutic Toxicity

Publisher： Bentham Science Publishers

E-ISSN： 1875-6220|4|1|59-68

ISSN： 1570-1638

Source： Current Drug Discovery Technologies, Vol.4, Iss.1, 2007-06, pp. : 59-68

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity

By Jensen Brian C   McLeod Howard L  

Pharmacogenomics, Vol. 14, Iss. 2, 2013-01 ,pp. : 205-213

Future Medicine

Access to resources Recommend Favorite

Risk Factors Determining Chemotherapeutic Toxicity in Patients with Advanced Colorectal Cancer

By Jansman F.G.A.  

Drug Safety, Vol. 23, Iss. 4, 2000-10 ,pp. : 255-278

Adis International

Access to resources Recommend Favorite

10 years of oral anticoagulant pharmacogenomics: what difference will it make? A critical appraisal

By Kurnik Daniel   Loebstein Ronen   Halkin Hillel   Gak Eva   Almog Shlomo  

Pharmacogenomics, Vol. 10, Iss. 12, 2009-12 ,pp. : 1955-1965

Future Medicine

Access to resources Recommend Favorite

Pharmacogenomics

By  

Current Drug Metabolism, Vol. 9, Iss. 3, 2008-03 ,pp. : 207-212

Bentham Science Publishers

Access to resources Recommend Favorite

Research Highlights: Highlights from the latest articles in pharmacogenomics of irinotecan/cisplatin toxicity

By Peters Godefridus J   Giovannetti Elisa  

Pharmacogenomics, Vol. 13, Iss. 13, 2012-10 ,pp. : 1445-1447

Future Medicine

Access to resources Recommend Favorite